

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Beechem, et al.)	Examiner: Unassigned
)	
Serial No.: 10/666,291)	Confirmation No. 9042
)	
Filing Date: September 17, 2003)	Group Art Unit: 1645
)	
For: Antibody Complexes and Methods)	Docket No. IVGN 703.1 CIP
for Immunolabeling)	
)	Response to Notice to Comply with
)	Requirements for Patent Applications
)	Containing Nucleotide Sequence and/or
)	Amino Acid Sequence Disclosure

Commissioner for Patents
U.S. Patent and Trademark Office
Washington, D.C. 20231

Dear Sir:

In advance of prosecution and in reply to the Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed on May 10, 2007, Applicants electronically submit herewith a copy of the Sequence Listing in computer readable form ("txt" file), a separate paper copy of the Sequence Listing for incorporation into the specification ("pdf" file), and request for amendment to the Specification specifically directing entry of the Sequence Listing into the application. Applicants herein petition for a one month extension as this response is hereby submitted on or before the one-month extended due date of August 10, 2007.

If additional fees are due, or if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees that are required are hereby authorized to be charged to our **Deposit Account No. 13-3900**.

Amendments to the Specification

Please add the following heading and paragraph to the Specification at page 1, immediately after the first paragraph that is captioned "Related Applications":

--Sequence Listing

The instant application contains a Sequence Listing which is incorporated herein by reference in its entirety.--

Remarks

I. Amendment to the Specification

Applicants have amended the Specification on page 1 to comply with the Sequence Listing requirements of 37 CFR 1.821(c). The amendment to the Specification merely adds language to incorporate the Sequence Listing, and adds no new subject matter. Therefore, Applicants respectfully request entry of this amendment.

II. Sequence Listing

Applicants submit herewith by electronic submission a printed document ("Paper Copy") of the Sequence Listing in portable document format ("pdf" file) for incorporation into the specification. Applicants further submit herewith a computer readable form ("CRF" Copy) of the Sequence Listing in the form of a text file ("txt" file). In accordance with 37 C.F.R. §§ 1.821(e-g) and 1.825(b) and (d) the undersigned states that both the Paper Copy and CRF Copy of the Sequence Listing are the same and do not include any new matter which goes beyond the disclosure of the application as filed. Applicants, therefore, respectfully request the Commissioner to include the Sequence Listing as part of the Application.

Conclusion

Prompt and favorable consideration of this Preliminary Amendment and entry of the submitted Sequence Listing is respectfully requested.

Respectfully submitted,

Date: August 10, 2007

/Koren Anderson Reg. No. 51,061/
Koren J. Anderson, Ph.D.

Invitrogen Corporation
Customer No. 23358
Phone: (541) 335-0165
Facsimile: (541) 335-0354